Advances in cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists
10.12206/j.issn.1006-0111.202006061
- VernacularTitle:SGLT-2抑制剂和GLP-1受体激动剂的心血管安全性研究进展
- Author:
Yanlan LAI
1
;
Aiwen HUANG
2
;
Lili ZHANG
2
;
Xiaolan LIAO
1
;
Lijun ZHAO
1
;
Hongtao SONG
2
Author Information
1. Department of Pharmacy, No. 900 Hospital of Joint Logistics Support Force of the PLA, Fuzhou 350025, China;Department of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
2. Department of Pharmacy, No. 900 Hospital of Joint Logistics Support Force of the PLA, Fuzhou 350025, China.
- Keywords:
SGLT-2 inhibitors;
GLP-1 receptor agonists;
type 2 diabetes;
cardiovascular safety
- From:
Journal of Pharmaceutical Practice
2020;38(6):496-500
- CountryChina
- Language:Chinese
-
Abstract:
Type 2 diabetes is a high risk factor for atherosclerotic cardiovascular disease. Studies have found that SGLT-2 inhibitor and GLP-1 receptor agonists have cardiovascular protective effects in patients with type 2 diabetes and cardiovascular disease. Therefore, from the aspects of cardiovascular safety test and its Meta-analysis and net-like Meta-analysis, the research progress of cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists is summarized.
